Tesamorelin Ipamorelin Blend: Which One Fits Your Goal

Tesamorelin vs Ipamorelin: Which One Should You Pick?

A tesamorelin ipamorelin blend runs both at once. For belly fat around the organs, tesamorelin has the evidence, from late-stage (Phase III) trials. Ipamorelin costs less, but no human trial cited here tests it for fat, muscle or sleep. The two hit different receptors. No trial cited here has tested them together.

Most write-ups frame this as a straight either-or. That framing misses the point. Both act on the same cells in the pituitary, the gland under the brain that releases GH. They just arrive through different doors. So the real question is rarely which one. It is whether one is enough for the goal you have.

This guide covers how each one works and what the fat data shows. It covers the shape of the GH pulse, the side effects, the dosing and the cost. GH is growth hormone. A goal-based table closes the page.

Background on the stronger of the two sits in the tesamorelin complete guide. The closest sibling matchup is tesamorelin vs sermorelin.

Affiliate disclosure: This post contains links to research-grade peptide suppliers. Underground Biohacking may earn a commission at no cost to you. See our recommended sources page for vendor-neutral guidance on where to source research peptides.

What Is the Tesamorelin Ipamorelin Blend?

It is two peptides drawn into one syringe. It is not one new molecule.

Some vendors sell the pair pre-mixed, and buyers hunt for a 2x blend. The label is marketing. What sits in the vial is still two drugs. And they work as a pair for one reason. They are not alike.

The first is a GHRH analogue. GHRH is growth hormone releasing hormone. It is the brain signal that tells the pituitary to act. Tesamorelin binds the GHRH receptor on the GH cells there. Those cells are called somatotrophs. Binding fires the Gs/cAMP/PKA cascade, a chain of signals inside the cell.

It also carries an N-terminal trans-3-hexenoyl group. That group acts as a shield. It blocks DPP-4, the enzyme that would cut the peptide apart. Falutz 2024 explains that the shield makes it last longer in the blood. The part that binds GHRH is left as it is. So the GH comes out in pulses, not as one flat line.

The second is built on the GHRP-1 scaffold. GHRP stands for growth hormone releasing peptide. Ipamorelin is a short chain of five amino acids. It binds a different receptor on those same cells. That one is the ghrelin receptor, or GHSR-1a. Binding opens the PLC/calcium route instead, a second signal chain that runs on calcium. Its defining trait is how picky it is. Older ghrelin mimetics, drugs that copy the hunger hormone ghrelin, switch on several hormones at once. GHRP-6 and GHRP-2 are two of them. In pigs, ipamorelin did not raise ACTH or cortisol, the stress hormone, more than GHRH did. That held even at doses more than 200 times the dose that gave half its peak GH release. None of the drugs tested changed prolactin, a hormone best known for milk production (Raun et al. 1998). ACTH is the pituitary signal that tells the body to make cortisol. PeptPedia 2026 and Ishida & Saitoh 2020 both back that edge over the first-generation GHRPs.

Now the point of the pair. Both receptors sit on the same cells. In a study of 18 healthy men, low doses of GHRP-6 were given with GHRH. Together they released more GH than the two alone would predict (Bowers et al. 1990). PeptideWiki 2026 calls it dual-pathway convergence. The two routes meet at the point where GH is let out of the cell, and each makes the other louder. No trial cited here has tested tesamorelin and ipamorelin together.

For a closer look at the receptor side, see the ipamorelin complete guide.

How Do Tesamorelin and Ipamorelin Shape Your GH Pulse?

The pulse data on the two are not alike. For tesamorelin there is a human trial. For ipamorelin the timing figure comes from a vendor blog.

The trial data on the first is clear. A 2011 study gave it to 13 healthy men with an average age of 45. They used 2 mg a day under the skin for two weeks. Basal GH, the level between pulses, went up. Mean overnight GH went up. GH peak area went up. IGF-1 rose by 181 micrograms per litre on average, at P less than 0.0001, so chance is a very unlikely cause. IGF-1 is the hormone that does most of GH's work in tissue. Glucose uptake driven by insulin held steady the whole time. That matters when IGF-1 is going to stay up for months.

Ipamorelin gives a short GH pulse after each shot. RealPeptides 2026 puts the window at two to three hours. No human trial cited here sets how often it should be given.

The biggest natural GH pulse of the day comes in the first hours of deep sleep. SourcePeptides 2026 sets out why a real pulse shape beats a flat one. It is the main case against injected GH.

Ipamorelin vs Tesamorelin: Which Cuts More Visceral Fat?

Tesamorelin has the human trial data. Ipamorelin has none cited here.

Its fat data come from late-stage trials in people. In the Phase III trial cited below, visceral fat fell by 10.9% over 26 weeks. In those who stayed on it for 12 months, it fell by about 18%. Visceral fat is the fat that wraps the organs. The effect lands there and leaves the fat under the skin much as it was. No human fat-loss trial of ipamorelin is cited here.

The pivotal trial took in 404 HIV-infected patients with too much belly fat. They used 2 mg a day under the skin. Over the first six months, visceral fat fell by 10.9%, or 21 cm squared. On placebo, a dummy shot, it fell by 0.6%. Those who stayed on the drug for 12 months saw a drop of about 18%. Waist size, trunk fat and body image distress scores all got better. Falutz 2010 saw no real glucose trouble. The drug was well tolerated. In those switched to placebo at six months, the early drop in visceral fat was lost.

A 2026 meta-analysis, a study that pools other studies, took in five randomised controlled trials (RCTs). In an RCT, chance decides who gets the drug. Badran 2026 put the mean gap in visceral fat at negative 27.71 cm squared, at P less than 0.001. Trunk fat fell by 1.18 kg against placebo. The authors found no serious side effects and no upset to blood sugar. A second look at the data from two Phase III trials went further. In the tesamorelin group it counted only people whose visceral fat fell by at least 8%; the placebo group was not filtered. Adrian et al. 2019 found more muscle density in all four trunk muscle groups after 26 weeks, against placebo. That covered rectus abdominis, the six-pack muscle, and the side wall of the belly. It also covered psoas major, a deep muscle running from the lower spine to the hip, and the muscles beside the spine. The result held at p less than 0.005 across groups.

For ipamorelin, the animal work is real but thin. Venkova et al. 2009 gave rats repeated doses into a vein after bowel surgery. Body weight gain, food intake and stool output all rose. That reads as a growth signal, not a fat-burning one. For ipamorelin on its own as a fat-loss tool, the human data is thin. It comes down to timing data and what can be read across from the GH literature.

Does Ipamorelin Make You Hungry?

Nobody has measured that well in people. In rats, one dose left food intake alone, but repeated doses raised it.

It acts on the ghrelin receptor, and ghrelin is the hunger hormone. In rats, ghrelin switched on NPY and AgRP neurons, brain cells that drive eating (Nakazato et al. 2001). These cells sit in the arcuate nucleus of the hypothalamus, a brain area that helps control feeding.

PeptPedia 2026 says there is no real appetite bump at normal doses. The rat study above found the opposite with repeated doses: food intake went up (Venkova et al. 2009). The pig study that showed ipamorelin left cortisol alone did not measure hunger (Raun et al. 1998).

GHRP-6 and MK-677 also act on the ghrelin receptor. Whether ipamorelin is easier on appetite than they are in people is not settled by the studies cited here.

What Are the Side Effects of Tesamorelin and Ipamorelin?

Their side-effect profiles differ. The label for the first lists injection-site reactions, joint pain and swelling.

The FDA-approved label for tesamorelin lists these in more than five percent of patients: injection-site erythema, pruritus, arthralgia, myalgia and peripheral oedema. In plain words, that is red skin, itching, joint pain, muscle pain and swelling. LiverTox 2018 notes that about five percent of trial patients stopped early. Muscle and joint pain drove most of that. The label says to monitor IGF-1, because tesamorelin raises it and the effects of long-term high IGF-1 are unknown. The label also warns that it can cause glucose intolerance. There is also the theoretical risk of feeding a pre-existing subclinical malignancy through the IGF-1 rise. In plain words, a cancer nobody has found yet. Every drug that acts on the GH axis shares that risk.

It has been tested in people whose metabolism is already under strain. In type 2 diabetic patients, twelve weeks of tesamorelin did not alter insulin response or blood sugar control. Mean IGF-1 stayed inside the normal range. The trial, Clemmons et al. 2017, took in 53 patients. It was run because injected GH is linked to insulin resistance.

For ipamorelin, the pig study above is the main evidence on hormone side effects (Raun et al. 1998). Ishida & Saitoh 2020 sum up that data. They describe very little knock-on effect on other hormones next to GHRP-6 and hexarelin.

How Often Do You Inject Each One?

The FDA label for the EGRIFTA SV form of tesamorelin sets 2 mg once a day under the skin. One shot, usually in the belly, fits into a morning or evening routine. There is no set upper dose for research use. The Phase III trial cited here used the same 2 mg a day.

Ipamorelin has no FDA label, so there is no official dose or schedule. The vendor figure above puts its GH window at two to three hours after a shot. Food raises somatostatin, a hormone that brakes GH release. That blunts the GH pulse.

The two do not compete for the same receptor. GHRH-R and GHSR-1a are separate, and their inside-the-cell routes meet further down. The version people research more often swaps CJC-1295 No DAC in for tesamorelin, because it costs less. CJC-1295 No DAC is another GHRH analogue.

What Does a Tesamorelin Ipamorelin Blend Cost?

Far more than ipamorelin on its own, and tesamorelin is the reason.

Tesamorelin is an approved drug. The branded form, Egrifta, is dear through the prescription channel. Research-grade material from compounding suppliers is easier to reach. It still costs more per milligram than ipamorelin does. Ipamorelin is one of the cheapest peptides on this axis.

The gap comes down to how each is made and where each sits in the market. The modified GHRH sequence and the owned synthesis route both carry a premium. Ipamorelin is a simpler five-amino-acid chain with a mature synthesis route and plenty of sellers competing on price.

So the sums work out like this. Ipamorelin gives a lower entry cost. Tesamorelin earns its price when belly fat around the organs is the one thing you are after.

Is a Tesamorelin and Ipamorelin Blend Right for Your Goal?

Here is the framing that matters. These are not rival products. They are two receptor classes inside one hormone axis. The choice turns on which route fits the goal, and on cost. For a third drug on the ghrelin side to compare against, see ipamorelin vs MK-677. Our CJC-1295 dosage guide compares CJC-1295 with tesamorelin.

References

• Stanley TL et al. (2011). Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab.
• Falutz J et al. (2010). Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr.
• Venkova K et al. (2009). Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther.
• Adrian S et al. (2019). The growth hormone releasing hormone analogue, tesamorelin, decreases muscle fat and increases muscle area in adults with HIV. J Frailty Aging.
• Falutz J (2024). Tesamorelin overview. ScienceDirect Topics.
• LiverTox (2018). Tesamorelin. NCBI Bookshelf.
• Clemmons DR et al. (2017). Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: a randomized, placebo-controlled trial. PLoS One.
• Badran AS et al. (2026). Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: a meta-analysis of randomized controlled trials. Obes Res Clin Pract.
• Ishida J, Saitoh M, et al. (2020). Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications.
• PeptPedia (2026). Ipamorelin: Mechanism, Effects and Research Studies.
• PeptideWiki (2026). CJC-1295 plus Ipamorelin Stack Guide.
• Raun K et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol.
• Nakazato M et al. (2001). A role for ghrelin in the central regulation of feeding. Nature.
• Bowers CY et al. (1990). Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab 70:975-82.

This content is for educational purposes only. These compounds are intended for research use. Nothing here is medical advice. A qualified clinician can advise on any health decision.